4.5 Review

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/17562864211035542

关键词

immunotherapy; inflammatory bowel disease; multiple sclerosis; psoriasis; rheumatoid arthritis

资金

  1. German Research Council (DFG) [CRC-TR-128]
  2. Hertie-Stiftung

向作者/读者索取更多资源

Advances in treatment of autoimmune diseases have led to more targeted and potent immunotherapies, posing challenges for physicians treating patients with multiple conditions. Some treatments are approved for multiple autoimmune disorders and offer new curative possibilities in related fields. Specific focus on common concomitant autoimmune conditions in patients with MS highlights potential overlaps and therapeutic combinations for more effective treatment.
The past decades have yielded major therapeutic advances in many autoimmune conditions - such as multiple sclerosis (MS) - and thus ushered in a new era of more targeted and increasingly potent immunotherapies. Yet this growing arsenal of therapeutic immune interventions has also rendered therapy much more challenging for the attending physician, especially when treating patients with more than one autoimmune condition. Importantly, some therapeutic strategies are either approved for several autoimmune disorders or may be repurposed for other conditions, therefore opening new curative possibilities in related fields. In this article, we especially focus on frequent and therapeutically relevant concomitant autoimmune conditions faced by neurologists when treating patients with MS, namely psoriasis, rheumatoid arthritis and inflammatory bowel diseases. We provide an overview of the available disease-modifying therapies, highlight possible contraindications, show pathophysiological overlaps and finally present which therapeutics can be utilized as a combinatory treatment, in order to 'kill two birds with one stone'.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据